Suggested remit - To appraise the clinical and cost effectiveness of depatuxizumab mafodotin within its marketing authorisation for treating newly diagnosed EGFR-amplified glioblastoma multiforme
Status In progress
Decision Selected
Process STA 2018
ID number 1466

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
04 June 2019 The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal which closed on 22 May 2019. The company that manufacturer depatuxizumab mafodotin have advised NICE that they are no longer pursuing a licence in the UK for this product for this indication. In light of this information NICE will not be progressing with the scoping exercise at this time. As the appraisal has been referred, NICE will continue to monitor any developments and will provide a further update in due course if required. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on
21 March 2017 Referral
21 March 2017 In progress. Topic referred

For further information on our processes and methods, please see our CHTE processes and methods manual